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Abstract
Pacemakers  and  other  cardiac  implantable  electronic  devices  (CIEDs)  have  long  been 
considered an absolute contraindication to magnetic resonance imaging (MRI), a crucial and 
growing imaging modality. In the last 20 years, protocols have been developed to allow MR 
scanning of CIED patients with a low complication rate. However, this practice has remained 
limited to a relatively small number of centers, and many pacemaker patients continue to be 
denied access to clinically indicated imaging. The introduction of MRI conditional pacemakers 
has  provided  a  widely  applicable  and  satisfactory  solution  to  this  problem.  Here,  the 
interactions of pacemakers with the MR environment, the results of MR scanning in patients 
with  conventional  CIEDs,  the  development  and  clinical  experience  with  MRI  conditional 
devices,  and future  directions  are  reviewed.                                            
Key words: magnetic resonance imaging (MRI); cardiovascular implantable electronic device 
(CIED);  pacemaker;  implantable  cardioverter-defibrillator  (ICD)                           
            
Introduction
Magnetic resonance imaging (MRI) has emerged as a leading imaging modality, and continues 
to develop new and innovative uses. It offers peerless imaging of the heart, vasculature, brain, 
and  other  soft  tissues,  finding  uses  in  almost  every  field  of  medicine,  including 
electrophysiology. This is illustrated by the ever-growing number of scans: in 2007, 90.2 MRI 
scans per 1000 population were performed in the United States, up from 40.0 in 1997.[1] In 
parallel  with  the  growth  of  MRI,  the  number  of  pacemakers  and  other  cardiovascular 
implantable  electronic  devices  (CIED) has  also steadily increased.  Each year,  an estimated 
200,000 patients in the United States receive a pacemaker; worldwide there are over 5 million 
pacemaker patients. An oft-quoted statistic is that an estimated 50-75% of CIED patients will 
require an MRI over the lifetime of their device.[2] However, given the potential for interaction 
between pacemakers and other CIEDs and the MRI environment, the presence of a pacemaker 
has long been considered an absolute contraindication to undergoing MRI.                           
MRI-CIED  interactions                                                   
Potential MRI-CIED interactions have been tested both in vitro and in vitro, and extensively 
reviewed.  Briefly,  these  include:                                       
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1.  Translational  attraction: the static  magnetic  field can exert  varying degrees of magnetic 
force and torque on the generator, with older models and ICDs being more susceptible at static 
field strengths up to 3 Tesla (T).[3-6] However, this is not likely of clinical significance, and 
we are not aware of any reports of this effect in humans.                                    
2.  Heating: this  is  of  most  concern  at  the  lead  tip,  due  to  resistive  heating  at  the  lead-
myocardium interface induced by both the radiofrequency (RF) current and gradient magnetic 
field. Temperature rises have been measured both in vitro and in an animal model, however 
other  experiments  have  been  more  reassuring  at  scan  settings  in  clinical  use.[4,5,7,8] 
Significant heating at the lead tip would be expected to be accompanied by cardiac troponin 
isoform release and an increase in pace capture threshold, however this combination has been 
reported in only 1 of a total of 251 MRI scans in which cardiac biomarkers and threshold were 
prospectively measured.[4,10-12] Nonetheless, >1V increases in threshold have been reported 
in some series,[9,10] transient loss of capture in an animal model[5], and loss of capture with 
high impedance, troponin elevation, and delayed threshold increase have all been reported in 
CIED  patients  undergoing  MRI.[13,14]                                         
3. Electrical current induction: this has been demonstrated in vitro and in animal studies, due 
to both the RF field and pulsed gradients.[8,15] Rapid capture of the myocardium could result 
in  hemodynamic  compromise  or  ventricular  fibrillation.  While  it  has  not  been observed in 
humans, it could be the basis for some of the fatalities which have occurred in unmonitored 
pacemaker  patients  undergoing  MRI.                                               
4.  Electromagnetic  interference  (EMI):  this  phenomenon  can  be  induced  by  the  MR 
environment  and  can  lead  to  incorrect  pacemaker  diagnostics,  rapid  ventricular  pacing,  or 
pacing inhibition.[5,17] Sensed EMI can be misinterpreted as atrial  or ventricular  high rate 
episodes.  It  can also lead to inhibition of pacing,  which if  prolonged,  could be lethal  to  a 
pacemaker-dependent patient. Tracking modes can lead to rapid ventricular pacing. In ICDs, 
sensed EMI, if interpreted as ventricular tachyarrhythmia can lead to inappropriate therapies.
[14]
5. Reed switch behavior: the static magnetic field leads to unpredictable reed switch position.
[7,18-23]  This  is  dependent  on  the  patient's  position  relative  to  the  bore  and  pacemaker 
orientation. Closure of the pacemaker reed switch leads to asynchronous pacing at the device 
specific "magnet rate", which, while a necessary feature, is undesirable for a prolonged period.
6.  Electrical or power-on reset: this  safety feature can be activated by battery depletion or 
EMI, and results in reprogramming to default (usually synchronous) settings. Devices which 
have undergone electrical  reset can be reprogrammed and the reset may be without clinical 
consequence. However, in a pacemaker-dependent patient, reset to a synchronous mode, along 
with inhibition due to sensed EMI, would lead to asystole. Sub-threshold stimulation at the 
default output is also a potential hazard. Electrical reset was reported in 8/51 (16%) cranial 
MRI  scans  at  3T,  but  7/115  (6.1%)  and  3/555  (0.7%)  studies  at  1.5T.[4,10,24]
6. Battery depletion: a transient decrease in voltage is seen in many CIEDs post MRI, returning 
to close to pre-MR values at follow-up, which seems to be a temporary effect of increased 
current drain during the scan.[4,7,10,24] This is not suspected to be of clinical significance.      
MRI of patients with conventional (MRI unsafe) pacemakers                             
Despite these risks, MRI examinations are sometimes of critical diagnostic value to patients 
with pacemakers and other CIEDs, and several centers  in Europe and North America have 
developed protocols for performing MRI in such patients.[4,7,9,10,23-25] Indeed, published 
reports exist on over a thousand patients with pacemakers and ICDs who have undergone MRI 
with a low but not zero complication rate. These protocols have been developed at centers with 
clinical  and experimental  expertise  in the field and it  is  important  to stress that the results 
obtained  may  not  be  applicable  where  such  experience  does  not  exist.  In  particular,  the 
presence of personnel with expertise in (and not merely familiarity with) CIED interrogation, 
programming  and  troubleshooting  is  a  pre-requisite,  as  well  as  those  trained  in  advanced 
cardiac life support (ACLS). Continuous, real-time monitoring during the scan by visual and 
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voice contact,  and with pulse oximetry as well  as ECG telemetry is  necessary,  as the MR 
environment causes sufficient electro-magnetic interference to render standard ECG tracings 
uninterpretable during scanning.[10,26] Generally, pacemaker-dependent patients' devices are 
programmed to an asynchronous mode, and non-pacemaker  dependent  patients'  devices are 
programmed  to  "monitor"  mode  (OSO),  to  avoid  competition  with  the  intrinsic  rhythm. 
Restrictions on scanning parameters, such as the use of transmit/receive rather than receive-
only coils[27] and limits on specific absorption rate, also apply although the latter has been 
challenged.[28] Patients with abandoned and/or fractured leads are also excluded from MRI, as 
such leads are more susceptible to lead tip heating.[29] Patients with devices implanted less 
than 6 weeks previously have been excluded in many published series. Although it may be 
assumed that the concern is for translational attraction of ferro-magnetic components of the 
leads, there are no components of the lead that would be attracted by static or variable magnetic 
fields.  The exclusion in  the EnRhythm MRI study was to  assure a stable  a pacing capture 
threshold so that any changes that might be seen (none detected) would be more clearly caused 
by the interaction  with the MRI environment.  Uneventful  MRI within hours of  pacemaker 
implantation  has  been  performed.[30]                                        
Yet even with this largely positive experience, some risk remains, and unusual manifestations 
of pacemaker-MRI interactions continue to be reported.[13,17,31] With the large numbers of 
CIED components both current and historical, and the number of relevant patient factors, the 
number  of  permutations  is  vast.  Efforts  to  track  the  safety  or  otherwise  of  MRI  in  large 
numbers of patients, such as the ongoing MagnaSafe Registry,[32] while important, will not be 
able  to  demonstrate  safety  across  all  CIED components  and  combinations  of  components. 
Regulators emphasize this aspect, and the need for adequately powered clinical trials.[33,34] 
Indeed,  in  the  US,  the  Centers  for  Medicare  and  Medicaid  Services  will  not  reimburse 
healthcare providers for MRI scans performed in patients with a conventional CIED, unless it is 
part of a clinical trial or registry. The ideal solution is the development of CIEDs that are MRI 
conditional.
MRI  conditional  pacemakers                                        
A number of steps can be taken to render CIEDs less susceptible  to the MR environment, 
including:
1.  Reduction  in  the ferromagnetic  content  of  the generator                               
2. Use of a Hall switch, which behaves in a predictable manner, instead of a reed switch     
3.  Modification  of  the  leads  to  reduce  lead  tip  heating                                
4.  Shielding  of  the  circuitry  to  render  it  immune  to EMI                              
5.  Protection  of  the  internal  power  supply                                           
6. Use of a dedicated MRI programming pathway to choose the appropriate pacing and sensing 
mode  for  the  patient                                               
MRI  protocols  and  procedures  can  also  be  chosen  to  reduce  the  chances  of  interaction:
1.  Lower  static  gradient  field  strength                                            
2.  Maximizing the distance between the CIED and the scanner                           
3.  Limiting  the  RF power                                                           
These innovations have led to the development of several MRI conditional pacing systems, the 
first  being  Medtronic's  RevoMRI  system.                                      
The publication of the EnRhythm MRI SureScan Pacing System Study was an important step 
towards  the  goal  of  rendering  MRI  broadly  available  to  pacemaker  patients.[35]  This 
represented the first clinical data on a pacing system designed  to  function  in  the  MRI 
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environment.  The  pacing  system,  consisting  of  the  EnRhythm  MRI  pulse  generator  and 
CapSureFix 5086MRI leads (Medtronic Inc., Minneapolis, MN) was implanted in 464 patients 
scheduled to undergo implantation of a pacemaker between 2007 and 2009. Patients were then 
randomized to undergo a non-clinically indicated MRI at 9-12 weeks post implant or not to 
undergo an MRI scan. The primary safety endpoint was the complication-free rate of the MRI 
procedure,  and the primary efficacy endpoint compared pace capture threshold and sensing 
between the MRI and control groups. A total  of 211 patients underwent an MRI and were 
followed for at least one month after the scan (mean ± SD 11.2 ± 5.2 months). Restrictions on 
the MRI scan similar to those frequently used in protocols for scanning conventional CIEDs 
were used: the static magnetic field strength was limited to 1.5T, maximum specific absorption 
rate (SAR) of 2W/kg and a maximum gradient slew rate of 200T/m/s. The isocenter of the RF 
transmitter coil was restricted to above C1 vertebra or below T12, meaning that in the trial, 
head and lumbar sequences were performed, although this restriction still permits imaging of 
most of the body. A dedicated MRI mode was programmed on, involving the completion of ten 
system integrity checks before the scan. Pacemakers were programmed to either asynchronous 
or non-stimulating  mode,  with output  at  5V at 0.5ms. No MRI related  complications  were 
observed, although 8 patients reported mild, self-limited symptoms that were either related or 
of unclear relationship to the MRI scan. The primary efficacy endpoint was also met as there 
were no differences in threshold or sensing parameters post MRI. While more patients died in 
the MRI group than the group that did not undergo MRI (9 versus 2), 3 died before the MRI 
scan, and the remaining 6 died of various causes not clearly related to the implant or the MRI 
scan.
Renamed the RevoMRI SureScan system, it received Food and Drug Administration (FDA) 
approval in February 2011. While the current version used in the US is based on the EnRhythm 
pacemaker, which lacks several advanced features such as automated capture determination, a 
second generation system (Advisa DR MRI SureScan) is available in Europe and has received 
investigational device exemption (IDE) from the Food and Drug Administration to undergo 
clinical trials  in the US. Due to redesign of the inner conductors the 5086MRI lead is one 
French size larger in diameter than the currently marketed CapSureFix Novus 5076 lead but is 
constructed more similarly to a legacy lead Medtronic 5068, which also has 2 filars and the 
same external diameter.  The extendable helix can require more turns to be fully deployed.  
Sometimes  the  helix  can  extend  suddenly  from  built  up  torque,  and  in  our  experience 
fluoroscopic monitoring of helix extension is required to ensure proper fixation. This may be 
responsible  for  a  very  slightly  increased  incidence  of  lead  dislodgement  noted  in  post-
marketing  performance  surveillance  (Medtronic,  personal  communication,  March  2012). 
However the lead otherwise appears to have comparable reliability to the CapSureFix Novus 
5076.
The other major pacemaker manufacturers also have MRI conditional devices either in use or in 
development.  None are at  present available in the US. Biotronik launched its Evia ProMRI 
pacemaker series, Safio 6.6F, Siello and Solia 5.6F MRI conditional leads (Biotronik SE & Co. 
KG, Berlin, Germany) in Europe in June 2010. St. Jude Medical’s (Sylmar, CA, USA) Accent 
MRI pacemaker and Tendril MRI 6.6Fr leads received the Conformité Européenne (CE) mark 
in April 2011 for 1.5T whole body MRI with SAR up to 4w/kg, and are currently undergoing 
regulatory assessment in the United States. The MRI Activator™ remote control device can be 
used to activate and deactivate an MRI mode, consisting of pre-programmed MRI settings, in 
the MRI suite. This is designed to improve workflow by eliminating the need for cardiology 
personnel to be present before and after the scan. Boston Scientific (Natick, Massachusetts, 
USA) and Sorin Group (Milan, Italy) are also in the process of developing MRI conditional 
systems. Biotronik also launched the first MRI conditional ICD – the Lumax 740 – in Europe 
in  November  2011.[36]  Published,  peer-reviewed clinical  data  are  not  yet  available  on the 
above systems, and none are available in the US.                                                 
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Diagnostic quality is substantially affected when the heart, and to a lesser extent the thorax, is 
imaged, however when the CIED is outside the field of view artifact is not seen with either 
MRI  conditional  or  conventional  CIEDs.[37-39]                                      
Labelling  and  terminology                                         
With the advent of MRI conditional pacing systems, a revised terminology was introduced by a 
panel representing multiple professional bodies.[40,41] Associated symbols for labeling and 
easy  visual  identification  are  presented  in  Table  1.  It  is  noteworthy  however,  that  the 
terminology is still  applied incorrectly,  even in the medical literature.  [42] MRI conditional 
conveys the meaning that the CIED can be present in the MR environment subject to specific  
conditions,  including  limits  on  static  field  strength,  gradient  slew  rate,  RF  fields,  and 
anatomical limits on the isocenter of the RF transmitter coil. MRI conditional CIEDs have not 
been clinically tested outside of these parameters.
Table 1. Current MRI terminology and labeling for pacemakers and ICDs. Adapted from 
reference 40.
Patient  selection  and  economic  impact                                  
With the availability of MRI conditional pacemakers, how should patient selection for MRI 
conditional  versus  conventional  pacemakers  be approached?  While  in  some cases,  such as 
patients who require recurring MRI scans for follow-up of medical conditions, the choice is 
easy, this represents a relatively small group and in most cases the decision on which device to 
implant  is  more  complex.  In  the  US,  the  RevoMRI  generator  and  leads,  depending  on 
contracting  can  be  about  10%  more  costly.  Therefore  the  strategy  of  implanting  MRI 
conditional  leads  with  a  conventional  generator,  in  anticipation  of  performing  a  generator 
change-out should an MRI be required in the future is weak. Use is also contraindicated in 
patients with conventional abandoned leads, which, as discussed above, present a higher risk 
than attached leads. While older patients have a higher short-term likelihood to encounter an 
indication to undergo an MRI scan than younger patients, the lifetime likelihood may be higher 
in  younger  patients.  With  the  availability  of  different  pacing  features  such  as  capture 
management  in the RevoMRI device in the US, other clinical  reasons might supercede the 
desire for an MRI conditional device. Currently, no specific guidelines have been developed to 
address this issue and the choice should ideally be made between the informed patient and his 
or  her  physician.                                            
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Conclusions  and  future  view                                        
Although MRI can be performed with a low complication rate in patients with conventional, 
MRI unsafe, pacemakers, this practice requires detailed knowledge and expertise, as well as 
specific resources, and will likely remain restricted to a small number of expert centers. MRI 
conditional  pacemakers  provide  a  comprehensive  solution  and,  even  with  the  scanning 
restrictions  on current  devices,  allow imaging of  almost  the entire  body (Table  2).  Future 
CIEDs are likely to be intentionally MRI conditional, but given the vast number of existing 
CIED components, MRI unsafe CIEDs will continue to present a dilemma for many years. MRI 
conditional technology will also have to keep pace with increasingly complex MR technology, 
including higher static field strengths, and clinical evaluation and relabeling of existing MRI 
conditional pacemakers may be necessary to achieve this.
Table 2: MRI conditions for current MRI conditional pacemakers. Only the Revo MRI system 
is available in the United States.
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